1
|
Ouldali N, Bagheri H, Salvo F, Antona D, Pariente A, Leblanc C, Tebacher M, Micallef J, Levy C, Cohen R, Javouhey E, Bader-Meunier B, Ovaert C, Renolleau S, Hentgen V, Kone-Paut I, Deschamps N, De Pontual L, Iriart X, Guen CGL, Angoulvant F, Belot A, Donzeau A, Aridi LE, Lety S, Leboucher B, Baur A, Jeusset L, Selegny M, Fedorczuk C, Lajus M, Bensaid P, Laoudi Y, Pons C, Robert AC, Beaucourt C, De Pontual L, Richard M, Goisque E, Iriart X, Brissaud O, Segretin P, Molimard J, Orecel MC, Benoit G, Bongiovanni L, Guerder M, Pouyau R, De Guillebon De Resnes JM, Mezgueldi E, Cour-Andlauer F, Horvat C, Poinsot P, Frachette C, Ouziel A, Gillet Y, Barrey C, Brouard J, Villedieu F, Ro V, Elanga N, Gajdos V, Basmaci R, Mutar H, Rouget S, Nattes E, Hau I, Biscardi S, Jurdi HE, Jung C, Semama D, Huet F, Zoccarato AM, Sarakbi M, Mortamet G, Bost-Bru C, Bassil J, Vinit C, Hentgen V, Leroux P, Bertrand V, Parrod C, Craiu I, Kone-Paut I, Durand P, Tissiere P, Claude C, Morelle G, Guiddir T, Borocco C, Delion F, Guillot C, Leteurtre S, Dubos F, Jouancastay M, Martinot A, Voeusler V, Languepin J, Garrec N, Demersay AC, Morand A, Bosdure E, Vanel N, Ughetto F, Michel F, Caujolle M, Blonde R, Nguyen J, Vignaud O, Masserot-Lureau C, Gouraud F, Araujo C, Ingrao T, Naji S, Sehaba M, Roche C, Carbasse A, Milesi C, Mazeghrane M, Haupt S, Schweitzer C, Romefort B, Launay E, Guen CGL, Ali A, Blot N, Tran A, Rancurel A, Afanetti M, Odorico S, Talmud D, Chosidow A, Romain AS, Grimprel E, Pouletty M, Gaschignard J, Corseri O, Faye A, Gaschignard J, Melki I, Ducrocq C, Benzoïd C, Lokmer J, Dauger S, Chomton M, Deho A, Lebourgeois F, Renolleau S, Lesage F, Moulin F, Dupic L, Pinhas Y, Debray A, Chalumeau M, Abadie V, Frange P, Cohen JF, Allali S, Curtis W, Belhadjer Z, Auriau J, Méot M, Houyel L, Bonnet D, Delacourt C, Meunier BB, Quartier P, Shaim Y, Baril L, Crommelynck S, Jacquot B, Blanc P, Maledon N, Robert B, Loeile C, Cazau C, Loron G, Gaga S, Vittot C, Nabhani LE, Buisson F, Prudent M, Flodrops H, Mokraoui F, Escoda S, Deschamps N, Bonnemains L, Mahi SL, Mertes C, Terzic J, Helms J, Idier C, Chenichene S, Ursulescu NM, Beaujour G, Hakim A, Miquel A, Rey A, Wiedermann A, Charbonneau A, Veauvy-Juven A, Ferry A, Mandelcwajg A, Rousseau A, Prenant A, Bourneuf AL, Filleron A, Robine A, Félix A, Parizel A, Labarre A, Cantais A, Ros B, Coulon B, Biot B, Dalichoux B, Fournier B, Cagnard B, Vanel B, Brossier D, Ménager B, Ozanne B, Marie-Jeanne C, Bergerot C, Chavy C, Guidon C, Fabre C, Galeotti C, Baker C, Ballot-Schmit C, Belleau C, Charasse C, Favel C, Toumi C, Ferrandiz C, Couturier C, Pouchoux C, Chomton-Cailliez M, Kevorkian-Verguet C, Brunet C, Manteau C, Mougey C, Santy C, Fitament C, Petriat C, Rebelle C, Charron C, Dartus M, Toulorge D, Guillou-Debuisson C, Bartebin D, Klein V, Broustal E, Desselas E, Marteau E, Bouvrot E, Delacroix E, Coinde E, Elnabhani L, Amouyal E, Chaillou E, Gabilly-Bernard E, Ruiz E, Thibault E, Robin E, Darrieux E, Blondel E, Socchi F, Cazassus F, Bajolle F, Lacin F, Madhi F, Zekre F, Guerin F, Boussicault G, Ginies H, Magloire G, Arnold G, Coulognon I, Sicard-Cras I, Kahn JE, Bordet J, Fausser JL, Baleine JF, Brice J, Gendras J, Pekin K, Norbert K, Karsenty C, Savary L, Martinat L, Lesniewski L, Charbonnier L, Alexandre L, Percheron L, Vincenti M, Selegny M, Lanzini M, Grisval M, Mercy M, Lampin ME, Desgranges M, Duperril M, Orcel MC, Audier M, Favier M, Carpentier M, Balcean M, Bonnet M, Jouret M, Delattre M, Levy M, Valensi M, Shum M, Dumortier M, Gelin M, Nemmouchi M, Williaume M, Sebaha M, Genetay-Stanescu N, Giroux N, Crassard N, Derridj N, Lachaume N, Werner O, Guilluy O, Richer O, Tirel O, Pauvert A, Casha P, Perez N, Gras P, Leger PL, Pinchou M, Mornand P, Largo P, Ibanez RC, Roulland C, Albarazi SH, Bichali S, Faton S, Schott A, Walser S, Guillaume S, Vincent S, Galene-Gromez S, Kozisek S, Maugard T, Blanc T, Navarro T, Lauvray T, Kovacs T, Launay V, Despert V, Lhostis V, Gall V, Micaelli X, Benadjaoud Y, Matoussi Z, Géniaux H, Facile A, Pietri T, Palassin P, Pinel S, Chouchana L, Callot D, Boulay C. Correction to “Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: A national post-authorization pharmacovigilance study”. Lancet Reg Health Eur 2022. [PMID: 35967266 PMCID: PMC9364716 DOI: 10.1016/j.lanepe.2022.100468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
2
|
Allaf B, Pondarre C, Allali S, De Montalembert M, Arnaud C, Barrey C, Benkerrou M, Benhaim P, Bensaid P, Brousse V, Dollfus C, Eyssette-Guerreau S, Galacteros F, Gajdos V, Garrec N, Guillaumat C, Guitton C, Monfort-Gouraud M, Gouraud F, Holvoet L, Ithier G, Kamdem A, Koehl B, Malric A, Missud F, Monier B, Odièvre MH, Joly P, Renoux C, Patin F, Pissard S, Couque N. Appropriate thresholds for accurate screening for β-thalassemias in the newborn period: results from a French center for newborn screening. Clin Chem Lab Med 2020; 59:209-216. [PMID: 32813673 DOI: 10.1515/cclm-2020-0803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Accepted: 07/06/2020] [Indexed: 11/15/2022]
Abstract
Objectives Newborn screening (NBS) for β-thalassemia is based on measuring the expression of the hemoglobin A (HbA) fraction. An absence or very low level of HbA at birth may indicate β-thalassemia. The difficulty is that the HbA fraction at birth is correlated with gestational age (GA) and highly variable between individuals. We used HbA expressed in multiples of the normal (MoM) to evaluate relevant thresholds for NBS of β-thalassemia. Methods The chosen threshold (HbA≤0.25 MoM) was prospectively applied for 32 months in our regional NBS program for sickle cell disease, for all tests performed, to identify patients at risk of β-thalassemia. Reliability of this threshold was evaluated at the end of the study. Results In all, 343,036 newborns were tested, and 84 suspected cases of β-thalassemia were detected by applying the threshold of HbA≤0.25 MoM. Among the n=64 cases with confirmatory tests, 14 were confirmed using molecular analysis as β-thalassemia diseases, 37 were confirmed as β-thalassemia trait and 13 were false-positive. Determination of the optimum threshold for β-thalassemia screening showed that HbA≤0.16 MoM had a sensitivity of 100% and a specificity of 95.3%, whatever the GA. Conclusions NBS for β-thalassemia diseases is effective, regardless of the birth term, using the single robust threshold of HbA≤0.16 MoM. A higher threshold would also allow screening for carriers, which could be interesting when β-thalassemia constitutes a public health problem.
Collapse
Affiliation(s)
- Bichr Allaf
- AP-HP (Assistance Publique-Hôpitaux de Paris), Robert-Debré Hospital, Newborn Screening Laboratory for Hemoglobinopathies, Paris, France
| | - Corinne Pondarre
- Department of General Pediatrics, Reference Center for Sickle Cell Disease, Hospital of Creteil, Créteil, France.,INSERM Unité 955, Paris XII University, Créteil, France
| | - Slimane Allali
- AP-HP, Department of General Pediatrics and Pediatric Infectious Diseases, Reference Center for Sickle Cell Disease, Necker Hospital for Sick Children, Paris Descartes University, Paris, France.,Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Paris Descartes - Sorbonne Paris Cite University, Imagine Institute, Inserm U1163, Paris, France.,Laboratory of Excellence GR-Ex, Paris, France
| | - Mariane De Montalembert
- AP-HP, Department of General Pediatrics and Pediatric Infectious Diseases, Reference Center for Sickle Cell Disease, Necker Hospital for Sick Children, Paris Descartes University, Paris, France.,Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Paris Descartes - Sorbonne Paris Cite University, Imagine Institute, Inserm U1163, Paris, France.,Laboratory of Excellence GR-Ex, Paris, France
| | - Cécile Arnaud
- Department of General Pediatrics, Reference Center for Sickle Cell Disease, Hospital of Creteil, Créteil, France
| | - Catherine Barrey
- Department of Pediatrics, Saint Camille Hospital, Bry-sur-Marne, France
| | - Malika Benkerrou
- Department of Child Hematology, Reference Center for Sickle Cell Disease Robert-Debré University Hospital, APHP, Paris, 75019,France
| | - Patricia Benhaim
- AP-HP, Department of Pediatrics, Jean Verdier Hospital, Bondy, France
| | - Philippe Bensaid
- Department of Pediatrics, Victor Dupouy Hospital, Argenteuil, France
| | - Valentine Brousse
- AP-HP, Department of General Pediatrics and Pediatric Infectious Diseases, Reference Center for Sickle Cell Disease, Necker Hospital for Sick Children, Paris Descartes University, Paris, France.,Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Paris Descartes - Sorbonne Paris Cite University, Imagine Institute, Inserm U1163, Paris, France.,Laboratory of Excellence GR-Ex, Paris, France
| | - Catherine Dollfus
- APHP, Department of Pediatric Hematology-Oncology Armand Trousseau Hospital, Sorbonne University Paris, Paris, France
| | | | - Frédéric Galacteros
- AP-HP, Sickle Cell Referral Center, Internal Medicine Unit, IMRB Team 2, UPEC, Labex GRex, Henri Mondor Hospital, Créteil, France
| | - Vincent Gajdos
- AP-HP Department of Pediatrics, Antoine Béclère University Hospital, Clamart, France.,Centre for Research in Epidemiology and Population Health, Villejuif, France.,Saclay University, Paris, France
| | - Nathalie Garrec
- Department of Pediatrics, Marne-la-Vallée Hospital, Jossigny, France
| | - Cécile Guillaumat
- Department of Pediatrics, Sud Francilien Hospital, 91100,Corbeil-Essonne, France
| | - Corinne Guitton
- AP-HP, Pediatrics Department, Reference Center for Sickle Cell Disease, Bicêtre Hospital, Le Kremlin Bicêtre, France
| | | | | | - Laurent Holvoet
- Department of Child Hematology, Reference Center for Sickle Cell Disease Robert-Debré University Hospital, APHP, Paris, 75019,France
| | - Ghislaine Ithier
- Department of Child Hematology, Reference Center for Sickle Cell Disease Robert-Debré University Hospital, APHP, Paris, 75019,France
| | - Annie Kamdem
- Department of General Pediatrics, Reference Center for Sickle Cell Disease, Hospital of Creteil, Créteil, France
| | - Bérengère Koehl
- Department of Child Hematology, Reference Center for Sickle Cell Disease Robert-Debré University Hospital, APHP, Paris, 75019,France
| | - Aurore Malric
- Department of Pediatrics, Saint-Denis Hospital, Saint-Denis, France
| | - Florence Missud
- Department of Child Hematology, Reference Center for Sickle Cell Disease Robert-Debré University Hospital, APHP, Paris, 75019,France
| | - Brigitte Monier
- Department of Pediatrics, Simone Veil Hospital, Montmorency, France
| | - Marie-Hélène Odièvre
- AP-HP, Department of General Pediatrics and Pediatric Infectious Diseases, Center for Sickle Cell Disease, Armand Trousseau Hospital, Sorbonne Université, Paris, France
| | - Philippe Joly
- Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Equipe "Biologie vasculaire et du globule rouge", Université Claude Bernard Lyon 1, COMUE Lyon, Villeurbanne, France.,Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), PRES Sorbonne, Paris, France.,UF Biochimie des pathologies érythrocytaires, Laboratoire de Biochimie et Biologie moléculaire Grand-Est, Groupement hospitalier Est, Hospices Civils de Lyon, Bron, France
| | - Céline Renoux
- Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Equipe "Biologie vasculaire et du globule rouge", Université Claude Bernard Lyon 1, COMUE Lyon, Villeurbanne, France.,Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), PRES Sorbonne, Paris, France.,UF Biochimie des pathologies érythrocytaires, Laboratoire de Biochimie et Biologie moléculaire Grand-Est, Groupement hospitalier Est, Hospices Civils de Lyon, Bron, France
| | - Franck Patin
- AP-HP (Assistance Publique-Hôpitaux de Paris), Robert-Debré Hospital, Newborn Screening Laboratory for Hemoglobinopathies, Paris, France
| | - Serge Pissard
- Laboratory of Excellence GR-Ex, Paris, France.,Institut National de la Sante et de la Recherche Médicale (INSERM) U 955 eq 2, Institut Mondor de Recherche Biomoléculaire (IMRB), Paris, France.,APHP, Molecular Genetics Department, Henri Mondor Hospital, Créteil, France
| | - Nathalie Couque
- AP-HP, Robert-Debré, Molecular Genetics Department, Paris, France
| |
Collapse
|
3
|
Lafolie J, Labbé A, L'Honneur AS, Madhi F, Pereira B, Decobert M, Adam MN, Gouraud F, Faibis F, Arditty F, Marque-Juillet S, Guitteny MA, Lagathu G, Verdan M, Rozenberg F, Mirand A, Peigue-Lafeuille H, Henquell C, Bailly JL, Archimbaud C. Assessment of blood enterovirus PCR testing in paediatric populations with fever without source, sepsis-like disease, or suspected meningitis: a prospective, multicentre, observational cohort study. Lancet Infect Dis 2018; 18:1385-1396. [PMID: 30389482 PMCID: PMC7164799 DOI: 10.1016/s1473-3099(18)30479-1] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/18/2018] [Revised: 07/04/2018] [Accepted: 07/17/2018] [Indexed: 01/24/2023]
Abstract
Background Enteroviruses are the most frequent cause of acute meningitis and are seen increasingly in sepsis-like disease and fever without source in the paediatric population. Detection of enterovirus in cerebrospinal fluid (CSF) specimens by PCR is the gold standard diagnostic test. Our aim was to assess a method of detecting enterovirus in blood specimens by PCR. Methods We did a prospective, multicentre, observational study at 35 French paediatric and emergency departments in 16 hospitals. We recruited newborn babies (aged ≤28 days) and infants (aged >28 days to ≤2 years) with fever without source, sepsis-like disease, or suspected meningitis, and children (aged >2 years to ≤16 years) with suspected meningitis, who were admitted to a participating hospital. We used a standardised form to obtain demographic, clinical, and laboratory data, which were anonymised. Enterovirus PCR testing was done in blood and CSF specimens. Findings Between June 1, 2015, and Oct 31, 2015, and between June 1, 2016, and Oct 31, 2016, we enrolled 822 patients, of whom 672 had enterovirus PCR testing done in blood and CSF specimens. Enterovirus was detected in 317 (47%) patients in either blood or CSF, or both (71 newborn babies, 83 infants, and 163 children). Detection of enterovirus was more frequent in blood samples than in CSF specimens of newborn babies (70 [99%] of 71 vs 62 [87%] of 71; p=0·011) and infants (76 [92%] of 83 vs 62 [75%] of 83; p=0·008), and was less frequent in blood samples than in CSF specimens of children (90 [55%] of 163 vs 148 [91%] of 163; p<0·0001). Detection of enterovirus was more frequent in blood samples than in CSF specimens of infants aged 2 years or younger with fever without source (55 [100%] of 55 vs 41 [75%] of 55; p=0·0002) or with sepsis-like disease (16 [100%] of 16 vs nine [56%] of 16; p=0·008). Detection of enterovirus was less frequent in blood than in CSF of patients with suspected meningitis (165 [67%] of 246 vs 222 [90%] of 246; p<0·0001). Interpretation Testing for enterovirus in blood by PCR should be an integral part of clinical practice guidelines for infants aged 2 years or younger. This testing could decrease the length of hospital stay and reduce exposure to antibiotics for low-risk patients admitted to the emergency department with febrile illness. Funding University Hospital Clermont-Ferrand.
Collapse
Affiliation(s)
- Jérémy Lafolie
- Université Clermont Auvergne, Centre National de la Recherche Scientifique (CNRS), Laboratory Microorganisms: Genome and Environment (LMGE), Clermont-Ferrand, France; Centre Hospitalier Universitaire (CHU) Clermont-Ferrand, Laboratoire de Virologie, Centre National de Référence Entérovirus Parechovirus, Clermont-Ferrand, France
| | - André Labbé
- Service de Pédiatrie, Clermont-Ferrand, France
| | - Anne Sophie L'Honneur
- Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Virologie, Paris, France
| | - Fouad Madhi
- Centre Hospitalier Intercommunal Créteil, Service de Pédiatrie Générale, Créteil, France
| | - Bruno Pereira
- Délégation Recherche Clinique and Innovation, Méthodologie, Biostatistique, Data-management, Clermont-Ferrand, France
| | - Marion Decobert
- Groupe Hospitalier Nord Essonne, Service de Pédiatrie et Néonatologie, Orsay, France
| | - Marie Noelle Adam
- Centre Hospitalier Sud Francilien, Laboratoire de Microbiologie, Corbeil Essonnes, France
| | - François Gouraud
- Grand Hôpital de l'Est Francilien, Service de Pédiatrie, Meaux, France
| | | | - Francois Arditty
- Centre Hospitalier de Versailles André Mignot, Service de Pédiatrie, Le Chesnay, France
| | | | | | | | | | - Flore Rozenberg
- Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Virologie, Paris, France
| | - Audrey Mirand
- Université Clermont Auvergne, Centre National de la Recherche Scientifique (CNRS), Laboratory Microorganisms: Genome and Environment (LMGE), Clermont-Ferrand, France; Centre Hospitalier Universitaire (CHU) Clermont-Ferrand, Laboratoire de Virologie, Centre National de Référence Entérovirus Parechovirus, Clermont-Ferrand, France
| | - Hélène Peigue-Lafeuille
- Université Clermont Auvergne, Centre National de la Recherche Scientifique (CNRS), Laboratory Microorganisms: Genome and Environment (LMGE), Clermont-Ferrand, France; Centre Hospitalier Universitaire (CHU) Clermont-Ferrand, Laboratoire de Virologie, Centre National de Référence Entérovirus Parechovirus, Clermont-Ferrand, France
| | - Cécile Henquell
- Université Clermont Auvergne, Centre National de la Recherche Scientifique (CNRS), Laboratory Microorganisms: Genome and Environment (LMGE), Clermont-Ferrand, France; Centre Hospitalier Universitaire (CHU) Clermont-Ferrand, Laboratoire de Virologie, Centre National de Référence Entérovirus Parechovirus, Clermont-Ferrand, France
| | - Jean-Luc Bailly
- Université Clermont Auvergne, Centre National de la Recherche Scientifique (CNRS), Laboratory Microorganisms: Genome and Environment (LMGE), Clermont-Ferrand, France
| | - Christine Archimbaud
- Université Clermont Auvergne, Centre National de la Recherche Scientifique (CNRS), Laboratory Microorganisms: Genome and Environment (LMGE), Clermont-Ferrand, France; Centre Hospitalier Universitaire (CHU) Clermont-Ferrand, Laboratoire de Virologie, Centre National de Référence Entérovirus Parechovirus, Clermont-Ferrand, France.
| | | |
Collapse
|
4
|
Khattab RM, Wahsh MMS, Khalil NM, Gouraud F, Huger M, Chotard T. Effect of nanospinel additions on the sintering of magnesia-zirconia ceramic composites. ACS Appl Mater Interfaces 2014; 6:3320-3324. [PMID: 24502185 DOI: 10.1021/am405184v] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Nanocrystalline magnesium aluminate (MA) spinel powder produced through a coprecipitation method and calcined at 900°C for 1 h was added to magnesia-zirconia composite in the range of 0-25 mass % and sintered at 1600°C for 2 h. Scanning electron microscope (SEM) and X-ray diffraction (XRD) techniques were used for studying the microstructure and the phase composition of the sintered composites. Bulk density, apparent porosity, volume shrinkage, and Young's modulus of the sintered composites were also investigated. The results revealed that the nanospinel addition up to 20 mass % increases the sintering ability and Young's modulus of the composite bodies. Microstructure showed that the presence of nanospinel and zirconia in the triple point between magnesia grains closed the gaps in the ceramic matrix and enhanced the compactness of the composites.
Collapse
Affiliation(s)
- R M Khattab
- Refractories, Ceramics and Building Materials Department, National Research Centre , 12311 Cairo, Egypt
| | | | | | | | | | | |
Collapse
|
5
|
Abstract
The respiratory toxicity of cannabis is well known today. Along with the classic cannabis 'joint', there are other ways of consuming it, which should be known. Smoking cannabis that has been cut with micro-particles of silicon dioxide may cause hemoptysis. We will describe here the case of a young 16-year-old man who was in the hospital because of hemoptic expectoration. The etiologic investigation was negative, in particular a thoracic scan and a bronchial fiberscope. Questioning the patient afterwards allowed us to discover the inhalation of cannabis 2 h before the hemoptysis, cannabis mixed with micro-particles of silicon dioxide. Stopping inhalation stopped the symptoms. Pediatricians should be familiarized with such practices. Silicon dioxide particles cause ENT problems or bronchial ones (coughing, spitting, hemoptysis, wheezing). Over the long term, the risk of silicosis cannot be excluded, although a longer and more complete exposure is necessary.
Collapse
Affiliation(s)
- M Monfort
- Service de pédiatrie générale, hôpital de Meaux, 6-8, rue Saint-Fiacre, BP 218, 77104 Meaux cedex, France.
| | | | | |
Collapse
|
6
|
Mahlaoui N, Minard-Colin V, Picard C, Bolze A, Ku CL, Tournilhac O, Gilbert-Dussardier B, Pautard B, Durand P, Devictor D, Lachassinne E, Guillois B, Morin M, Gouraud F, Valensi F, Fischer A, Puel A, Abel L, Bonnet D, Casanova JL. Isolated congenital asplenia: a French nationwide retrospective survey of 20 cases. J Pediatr 2011; 158:142-8, 148.e1. [PMID: 20846672 DOI: 10.1016/j.jpeds.2010.07.027] [Citation(s) in RCA: 62] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/31/2009] [Revised: 06/21/2010] [Accepted: 07/16/2010] [Indexed: 01/25/2023]
Abstract
OBJECTIVE To better describe the natural history, mode of inheritance, and the epidemiological and clinical features of isolated congenital asplenia, a rare and poorly understood primary immunodeficiency. STUDY DESIGN A French national retrospective survey was conducted in hospital pediatric departments. A definitive diagnosis of ICA was based on the presence of Howell-Jolly bodies, a lack of detectable spleen, and no detectable cardiovascular malformation. RESULTS The study included 20 patients (12 males and 8 females) from 10 kindreds neither related to each other nor consanguineous. The diagnosis of ICA was certain in 13 cases (65%) and probable in 7 cases (35%). Ten index cases led to diagnosis of 10 additional cases in relatives. Five cases were sporadic and 15 were familial, suggesting autosomal dominant inheritance. Median age was 12 months at first infection (range, 2-516 months), 11 months at diagnosis of asplenia (range, 0-510 months), and 9.9 years at last follow-up (range, 0.7-52 years). Fifteen patients sustained 18 episodes of invasive bacterial infection, caused mainly by Streptococcus pneumoniae (61%). Outcomes were poor, with 9 patients (45%) dying from fulminant infection. CONCLUSIONS ICA is more common than was previously thought, with an autosomal dominant inheritance in at least some kindreds. Relatives of cases of ICA should be evaluated for ICA, as should children and young adults with invasive infection.
Collapse
Affiliation(s)
- Nizar Mahlaoui
- Pediatric Immunology-Hematology Unit, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, University Paris Descartes, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Bouchireb K, Dodille A, Ponvert C, Gouraud F, Dubrel M, Brugières L. Management and successful desensitization in methotrexate-induced anaphylaxis. Pediatr Blood Cancer 2009; 52:295-7. [PMID: 18855892 DOI: 10.1002/pbc.21742] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Anaphylactic/anaphylactoid reactions to methotrexate are rare. In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression. In such patients, desensitization may enable the patient to continue treatment with methotrexate. We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate. Skin tests with methotrexate were not performed because their diagnostic value is controversial. Desensitization with methotrexate was successful and allowed the patient to complete 12 additional courses of chemotherapy. Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.
Collapse
Affiliation(s)
- Karim Bouchireb
- Department of Pediatrics and Adolescent Oncology, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | |
Collapse
|
8
|
Adam M, Vincenot A, Gouraud F, Harvel C, Perot C, Portnoi MF, Andre-Kerneis E, Giraudier S, Leverger G, Favier R. [Transient myeloproliferative disorder in a neonate without Down syndrome]. Ann Biol Clin (Paris) 2007; 65:569-73. [PMID: 17913678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2007] [Accepted: 07/02/2007] [Indexed: 05/17/2023]
Abstract
We report a new case of transient myeloproliferative disorder (TMD) in a non Down syndrome neonate. The cytogenetic and molecular studies within from the blood blast cells identified a trisomy 21 and a partial deletion in exon 2 of the transcription factor GATA1. Spontaneous regression of the TMD was achieved at the age of 1 month as the clonal and molecular abnormalities. A survey by periodic cytological examinations of peripheral blood cells and GATA1 mutation analysis was instituted since three years and has not detected up to date acute leukaemia.
Collapse
Affiliation(s)
- M Adam
- AP-HP, Services d'hématologie biologique et clinique, Hôpital d'enfants Armand Trousseau, Paris
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Vaudre G, Trocmé N, Landman-Parker J, Maout F, Tabone MD, Tourniaire B, Gouraud F, Dollfus C, Auvrignon A, Leverger G. [Quality of life of adolescents surviving childhood acute lymphoblastic leukemia]. Arch Pediatr 2005; 12:1591-9. [PMID: 16216482 DOI: 10.1016/j.arcped.2005.07.017] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2004] [Accepted: 07/28/2005] [Indexed: 10/25/2022]
Abstract
PURPOSE To evaluate how adolescents and young adults cured of acute lymphoblastic leukemia (ALL) treated during childhood have integrated the disease, and possible death related to cancer. Particularly, we have focused on experiences related to diagnosis announcement, hospitalisation and treatments and consequences on their social, psychological and somatic behaviour. PATIENTS Forty-one patients cured of ALL have been enrolled in the study and answered one interview with clinical psychologist or research nurse. RESULTS Although 60% of the patients argued that they think rarely of their disease, 10% thought about it every day. Traumatic evidence was detectable in most of them. Physical pain was the most reported stress, mainly during hospitalisation (93%), as well as psychological suffering (83%). Afterwards, the mostly often-reported stress was psychological pain (61%). Sixty-six percent declared that they still experience psychological and health consequences at the time of the interview, in some cases reported as a handicap in their life. In 83% of the cases they considered themselves as cured, nevertheless fear of relapse persisted in 1/3. Ninety percent said they have a pleasant life, 56% did not like to talk about leukaemia and 70% thought they could have died. For 85%, disease has been the most important event of their life and 75% testify to repercussions of the disease on their family (family relationship changes, overprotection, siblings difficulties). CONCLUSION Most of these patients declared to be 'as the others' and developed life projects, but overcoming the pain experience of the disease remained difficult. This study emphasized the need for long-term continuous information and reinforces the importance of addressing treatment psychological and physical pain mainly after the initial hospitalisation period.
Collapse
Affiliation(s)
- G Vaudre
- Service d'hématologie et d'oncologie pédiatrique, hôpital d'enfants Armand-Trousseau, Assistance publique-hôpitaux de Paris, 75012 Paris, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Trocmé N, Vaudre G, Landman Parker J, Maout F, Tabonne M, Tournaire B, Gouraud F, Leverger G. CO45 Pédiatrie générale et spécialisée L'impact d'une leucemie aiguë lymphoblastique (LAL) survenue dans l'enfance sur le vecu des adolescents (ou jeunes adultes) aujourd'hui gueris. Arch Pediatr 2003. [DOI: 10.1016/s0929-693x(03)90511-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
11
|
de Montalembert M, Belloy M, Bernaudin F, Gouraud F, Capdeville R, Mardini R, Philippe N, Jais JP, Bardakdjian J, Ducrocq R, Maier-Redelsperger M, Elion J, Labie D, Girot R. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease. J Pediatr Hematol Oncol 1997; 19:313-8. [PMID: 9256830 DOI: 10.1097/00043426-199707000-00009] [Citation(s) in RCA: 82] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
PURPOSE To observe the safety and efficacy of hydroxyurea (HU), a drug that stimulates fetal hemoglobin (Hb F) production, in previously severely ill children with sickle cell disease. PATIENTS AND METHODS HU was given in an uncontrolled study to 35 children with sickle cell disease, aged from 3 to 20 years, suffering from frequent painful crises. Mean duration of treatment was 32 months (range: 12-59 months). RESULTS HU induced an increase in Hb F levels in all children out one; this increase was maximal after 9 months of treatment, was largely sustained thereafter, and was related to HU dose and inversely to patients' age. We also noted an apparent reduction in crisis, which occurred principally after 3 months of therapy and did not seem strictly correlated with the rise in Hb F level. No serious hematopoietic complication was observed. Growth curves and sexual development were not modified. CONCLUSION Our data support the efficacy of HU in reducing painful events in children with sickle cell disease. Short- and middle-term tolerances are good. Thus, we think that HU can be given to children affected by frequent and severe painful crises. We recommend, however, very cautious use of this drug, because its long-term effects in children are still unknown.
Collapse
|
12
|
Iniguez JL, Leverger G, Dollfus C, Gouraud F, Garnier R, Beauvais P. Lead mobilization test in children with lead poisoning: validation of a 5-hour edetate calcium disodium provocation test. Arch Pediatr Adolesc Med 1995; 149:338-40. [PMID: 7858698 DOI: 10.1001/archpedi.1995.02170150118024] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- J L Iniguez
- Department of Pediatric Onco-Hematology, Armand Trousseau Children's Hospital, Paris, France
| | | | | | | | | | | |
Collapse
|
13
|
Montfort-Gouraud M, Pigot JY, Gouraud F. [Cholelithiasis in a child treated with ceftriaxone]. Arch Fr Pediatr 1993; 50:722-723. [PMID: 8002753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
|
14
|
Iniguez JL, Gouraud F, Leverger G, Lasfargues G. [Lead poisoning in children. Validation of a 5-hour urinary lead provocation test]. J Toxicol Clin Exp 1992; 12:341-5. [PMID: 1295991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- J L Iniguez
- Unité d'hématologie et d'oncologie pédiatrique, Hôpital d'enfants Armand-Trousseau, Paris, France
| | | | | | | |
Collapse
|
15
|
François B, Gouraud F, Garbarg-Chenon A, Despretz P, Leverger G. [Macrophage activation syndrome and dysgammaglobulinemia. Role of the Epstein-Barr virus]. Ann Pediatr (Paris) 1992; 39:245-7. [PMID: 1319695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The case of a five-year-old boy with macrophage activation syndrome and Epstein-Barr virus infection is reported. Several unusual features were found, including an early major increase in IgA levels, persistent oligoclonal gammapathy, and delayed development of anti-EA antibodies accompanied with an increase in anti-VCA antibodies. Despite the negative family history, an immune deficit and Purilo syndrome are discussed as possible diagnoses in this child.
Collapse
Affiliation(s)
- B François
- Unité d'Hématologie et d'Oncologie Pédiatrique, Hôpital Trousseau, Paris
| | | | | | | | | |
Collapse
|
16
|
Carlier-Mercier L, Fontaine JL, Boccon-Gibod L, Girardet JP, Josset P, Gouraud F, Pinturier MF. [A rare cause of neonatal exudative enteropathy: congenital Langerhans cell histiocytosis (histiocytosis X)]. Arch Fr Pediatr 1992; 49:199-201. [PMID: 1610278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
A case of Langerhans cell histiocytosis is reported in a neonate. Intestinal involvement was especially diffuse and severe, presenting as a protein-losing enteropathy secondary to massive mucosal infiltration by histiocytic cells. The infant died at the age of 3 1/2 months despite therapy with corticosteroids and vinblastine then etoposide and interferon. Such an outcome confirmed the severity of forms with neonatal onset and digestive involvement.
Collapse
Affiliation(s)
- L Carlier-Mercier
- Service de Gastroentérologie et Nutrition Pédiatriques, Hôpital Trousseau, Paris
| | | | | | | | | | | | | |
Collapse
|
17
|
Gouraud F, Leverger G. [Anemia in children. Diagnostic orientation]. Rev Prat 1992; 42:527-30. [PMID: 1604180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- F Gouraud
- Unité d'hématologie oncologie pédiatrique, hôpital d'enfants Armand-Trousseau, Paris
| | | |
Collapse
|
18
|
Damay M, Chevalier MC, Gouraud F, Jabado N, Varache C, Landman-Parker J, Leverger G. [Isolated Candida albicans meningitis after treatment of B lymphoma]. Arch Fr Pediatr 1992; 49:113-5. [PMID: 1580734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
A case of candida meningitis occurring in a child treated for a lymphoma is reported. Diagnosis was made with Candida albicans culture in the CSF. Blood cultures were negative. Cerebral CT scan was normal. No other localization was found. The child was successfully treated by amphotericin B (initially with 5-fluorocytosin). Fluconazole was continued orally later on. This case is noteworthy by the absence of other localization, the favourable evolution and its occurrence in childhood. The therapeutic attitude and prevention are discussed.
Collapse
Affiliation(s)
- M Damay
- Service de Pédiatrie, Hôpital du Mans
| | | | | | | | | | | | | |
Collapse
|
19
|
Tabone MD, Gouraud F, Tillous-Borde I, Couprie C, Leverger G. [Congenital long QT syndrome disclosed during the induction treatment of acute promyelocytic leukemia]. Arch Fr Pediatr 1991; 48:739-40. [PMID: 1793355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
20
|
Iniguez JL, Gouraud F, Leverger G, Lasfargues G. [Lead poisoning in a child, resistant to treatment]. Presse Med 1991; 20:1953. [PMID: 1837101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
|
21
|
Leblanc T, Leverger G, Baruchel A, Gouraud F, Yver A, Schaison G. Infections fongiques hépato-spléniques chez des enfants neutropéniques. Med Mal Infect 1991. [DOI: 10.1016/s0399-077x(05)80147-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
22
|
Krief S, Merzeau C, Jabado N, Gouraud F. [Iconographic rubric. A case of leukoencephalopathy following intraventricular injection of methotrexate]. Arch Fr Pediatr 1991; 48:277-8. [PMID: 2069482] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- S Krief
- Service de Radiologie, Hôpital Trousseau, Paris
| | | | | | | |
Collapse
|
23
|
Yver A, Leverger G, Iniguez JL, Gouraud F, Lamour C, Garnier R, Turbier C, Delour M, Lasfargues G. [Lead poisoning in children. Apropos of 129 cases]. Arch Fr Pediatr 1991; 48:185-8. [PMID: 1904704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
One hundred and twenty nine children with chronic lead poisoning were followed from August 1985 to July 1989. Old lead paint was recognized as the contaminant source at home. Pica of paint flakes was the main mode of intoxication. Children were classified according to the Center for Disease Control 1985 as follows: class IV (39 cases), class III (45 cases), class II (30 cases), class I (15 cases). Nineteen of those in class IV had blood lead levels above 700 micrograms/l and received BAL + EDTA followed by EDTA alone for a mean of 4.6 +/- 3.5 courses. With this treatment, blood lead level decreases were 50 +/- 17%. Nine of these class IV children had an evaluation at last 3 months after the last chelation course: 5 became class I or II, and 2 class III with a negative provocative test. The remaining 20 children in class IV were given a mean of 2.7 +/- 1.4 courses of EDTA. Blood lead levels decreased by 52 +/- 15%; 11 children were evaluable at least 3 months after the last chelation course: 4 became class I, and 7 class II. Thus overall 80% of class IV moved under treatment to class I or II. Among those 45 children in class II, 30 underwent a provocative test and 24 one to three courses of EDTA: 8 were further studied: 3 became class I and 5 class II. Combination of screening, medical treatment and sociocultural approach led to avoid acute effects of severe chronic childhood lead poisoning. The efficacy of such an approach in preventing chronic effects has still to be evaluated.
Collapse
Affiliation(s)
- A Yver
- l'Unité d'Hématologie et d'Oncologie Pédiatrique, Hôpital Trousseau, Paris
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Olivier C, Gouraud F. [Treatment of pneumococcal infections in children]. Ann Pediatr (Paris) 1989; 36:575-9. [PMID: 2589771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
25
|
Gouraud F, Sinnassamy P, Bensman A, Tchernia G, Boffa GA. Polycythemia in a young patient with chronic renal insufficiency and bilateral hydronephrosis. Int J Pediatr Nephrol 1987; 8:51-3. [PMID: 3583559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|